RA-Therapie mit Januskinase-Inhibitoren – Muss wirklich über ein um 40 % erhöhtes Krebsrisiko aufgeklärt werden?
- DOI
- 10.1007/s00393-026-01822-4
- Published
- 2026-05-28
- Container
- Zeitschrift für Rheumatologie
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s00393-026-01822-4,
title = {RA-Therapie mit Januskinase-Inhibitoren – Muss wirklich über ein um 40 \% erhöhtes Krebsrisiko aufgeklärt werden?},
author = {Markus Gaubitz},
year = {2026},
journal = {Zeitschrift für Rheumatologie},
doi = {10.1007/s00393-026-01822-4},
url = {https://doi.org/10.1007/s00393-026-01822-4}
}RIS
TY - JOUR TI - RA-Therapie mit Januskinase-Inhibitoren – Muss wirklich über ein um 40 % erhöhtes Krebsrisiko aufgeklärt werden? AU - Markus Gaubitz PY - 2026 JO - Zeitschrift für Rheumatologie DO - 10.1007/s00393-026-01822-4 UR - https://doi.org/10.1007/s00393-026-01822-4 ER -
APA
Gaubitz, M. (2026). RA-Therapie mit Januskinase-Inhibitoren – Muss wirklich über ein um 40 % erhöhtes Krebsrisiko aufgeklärt werden?. Zeitschrift für Rheumatologie. https://doi.org/10.1007/s00393-026-01822-4
Source records
- crossref · retrieved 2026-09-25T14:14:08.931Z